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Abstract
Complications associated with the use of bisphosphonate (BP) have risen over the years
due to an increase in the prescription of BP. BP-related osteonecrosis of jaw (BRONJ), one
of the complications linked to the consumption of BP, greatly affects patients with minor
dental trauma, incurring a long healing period. While BRONJ afflicts only a minority of pa-
tients prescribed with BP, BRONJ is a multigenic disease affected both by environmental
and genetic factors having a distinctive phenotype. This study aims to discover genetic bio-
markers associated with BRONJ via whole exome sequencing (WES) followed by statistical
analysis. Sixteen individuals who had been prescribed with bisphosphonate medication
and diagnosed as BRONJ were chosen and each individual’s saliva sample was collected
for WES. 126 randomized subsamples from the GSK project representing 109 male and 17
female Koreans were used as a control data set. Fisher’s exact test was carried out to as-
sess the significance of genetic variants in BRONJ patients. Gene set enrichment analysis
(GSEA) (DAVID Bioinformatics Resource 6.7) was used to perform a cluster analysis of var-
iants found from Fisher‘s exact test. The results from this study suggest that BRONJ-induc-
ing factors are genetically associated and BRONJ occurs due to the malfunctioning of post-
translational modification in osteoclast leading to the impairment of cell morphology
and adhesion.
Introduction
Bisphosphonates (BP) are a commonly prescribed medication to treat bone metastases, multi-
ple myeloma, osteoporosis, and other bony diseases [1,2,3]. It is prescribed at 73 percent of
physician visits for osteoporosis in the United States [4]. No significant side effects have been
reported but patients prescribed with BP over a long period tend to experience complications
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during healing after minor trauma in dentistry such as tooth extraction, periodontal surgical
operation, and tooth operations.
In 2003, it was first reported that bisphosphonate-related osteonecrosis of jaw (BRONJ) de-
rives from the exposure and necrosis of alveolar bone, pain, infection, and abscess formation
[5]; several other cases have since followed [6,7,8,9]. Many groups have recently published rec-
ommendations or guidelines on prevention, staging, and management strategies for BRONJ
[10,11,12,13,14,15,16,17,18,19,20,21]. Nevertheless, much needs to be done concerning the in-
cidence, pathogenesis, treatment, and prevention of BRONJ.
Patients who have received or been exposed to bisphosphonate and have not had craniofa-
cial region radiation therapy can be diagnosed with BRONJ if they have exposed jaw bone that
has not healed within 8 weeks after identification by a health care provider. The 8-wk duration
is consistent with the time frame in which most trauma, extractions, and oral surgical proce-
dures would have resulted in soft tissue closure and exposed bone would no longer be present
[22].
The incidence of the disease seems to be relatively low in patients receiving oral bisphospho-
nates for osteoporosis or Paget’s disease and considerably higher in patients with malignancy
receiving high doses of intravenous bisphosphonates. The mean incidence after intravenous
application was 7% and the overall incidence of BRONJ after oral bisphosphonate application
was 0.12% [23]. In a clinical investigation of BRONJ in patients with malignant tumors, the dis-
ease recurred at the same sites in 7 out of 20 patients (37%) and at different sites in 3 patients
(16%) [24]. Not all patients receiving BP treatment experience BRONJ, a clinical study showing
an estimated risk of between 0.8% and 12% [25]. These varying statistical values imply that
BRONJ is a multifactorial disease involving several factors in combination.
BP is known to inhibit osteoclastic bone resorption via attraction to and localization in
areas of the bone undergoing inflammation or resorption. Recently, substantial evidence has
emerged supporting such actions of BPs. Nitrogen-containing BPs are subsequently phagocy-
tized and internalized by osteoclasts, wherein they inhibit the mevalonate pathway during cho-
lesterol synthesis [26]. Such obstruction causes impairment of small GTPases of the Ras family,
which are known to be involved in cytoskeletal activity of bone-resorbing osteoclasts [26]. The
internalized BPs triggers apoptosis of osteoclasts, inhibiting osteoclast-mediated bone resorp-
tion [27,28].
Several studies on BRONJ-linked environmental risk factors have examined issues such as
the use of intravenous vs. oral BPs [29], concomitant use of chemotherapy [30], treatment with
glucocorticoid [10] or thalidomide [31], length of exposure to BP treatment [32,33,34], the
presence of comorbid conditions such as obesity [35,36], alcohol and/or tobacco abuse and
pre-existing dental or periodontal disease. Among these, dental trauma such as tooth extrac-
tion is known to be the most common immediate precipitation risk factor [37].
Other predisposing factors for BRONJ are age, race, smoking, obesity, cancer diagnosis, and
poor oral health, though these only account for a small percentage of the entire risk [32,35,38].
Since patients with BP medication undergo similar biological effects due to the intake of BP
and considering that only a small number of BP users experience BRONJ, it can be hypothe-
sized that genetic susceptibility is conferred by multiple genes regulating the metabolism of BP
or skeletal homeostasis with small variations [39]. If so, BRONJ, like many other complex trait
diseases, may be caused by a combination of environmental and genetic risk factors.
Previous genetic association studies found various genes such as vascular endothelia growth
factor (VEGF), collagen Type 1 A 1 (COLIAI), cytochrome P450 subfamily 2 polypeptide 8
(CYP2C8), farnesyl disphosphate synthase gene, Matrix metalloproteinase-9 (MMP9), and per-
oxisome proliferator-activated receptor gamma (PPARG) [40,41,42,43,44,45,46,47,48,49] to be
associated with risk of developing BRONJ. Until 2004, genetic research depended on advanced
Investigation of BRONJ Biomarkers
PLOS ONE | DOI:10.1371/journal.pone.0118084 February 10, 2015 2 / 14
Competing Interests: The authors have declared
that no competing interests exist.
technologies and case control studies primarily identified only a small number of variants relat-
ed to BRONJ.
Case-specific approaches have attempted to accommodate small case numbers. The first ge-
nome-wide association study (GWAS) reported the rs1934951 (CYP2C8) single nucleotide
polymorphism (SNP) was associated with BRONJ in multiple myeloma (MM) [50]. However,
two other studies reported that this SNP showed no correlation with jaw osteonecrosis in pa-
tients suffering from prostate cancer and neither research group could confirm a significant as-
sociation between polymorphisms in the CYP2C8 gene and the risk of developing
osteonecrosis of the jaw in patients with MM receiving treatment with BP in an independent
series [51,52]. So far, no single gene has been verified as a risk factor despite numerous GWAS
studies. This is due to the limitation of GWAS in representing SNPs when only five thousand
to one million bases out of three billion human base pairs are analyzed. Newly discovered ge-
netic indicators revealed the limits of GWAS and gave rise to many discussions regarding miss-
ing heritability in GWAS. A relatively new method, next generation sequencing (NGS),
accommodates these limitations.
In previous studies, a SNP array is commonly used to identify variants within a certain
range. One of the limitations of SNP arrays is that the analysis is done using the preexisting ref-
erence SNP. The goal of this study is to find novel variants and to include them in our analysis
of both rare and common variants relating to BRONJ. Therefore, Whole exome sequencing
(WES), NGS technology, is more appropriate for the purpose of this study.
NGS technology shifted genetic research from investigating known candidate genes to re-
vealing gene mutations and discovering candidate genes by comparing case and control. Be-
cause NGS targets the exome, mutations in non-synonymous variants, splice sites, and coding
indels can be identified, particularly by focusing on non-synonymous mutations in which
changes in amino acids affect protein function. However, WES alone may not provide prag-
matic results in a multi-genic disease like BRONJ due to the extensive raw data, pointing out
the need to integrate data management and computational screening. Incorporation of Gene
Set Enrichment Analysis (GSEA) and a protein functional network study of WES data may de-
fine enriched functions related with genetic variants implicitly related to BRONJ. GSEA pro-
vides a novel way to functionally analyze a large number of variants in a high-throughput
fashion by classifying them into gene groups based on their annotation term co-occurrence.
The objective of this study was to discover genetic biomarkers associated with BRONJ via WES
GSEA, as well as network analysis followed by statistical analysis and comparison with
known genes.
Material and Methods
1. Ethics Statement
All research involving human subjects or human data was approved by the Institutional Review
Board of Yonsei University College of Dentistry (Yonsei IRB No. 2–2014–0018). All clinical in-
vestigation was performed in accordance with the Declaration of Helsinki. Written informed
consent was obtained from all subjects prior to participation.
2. Patient Selection
Sixteen individuals between 55 and 90 with BRONJ were analyzed using massively parallel se-
quencing in this study (1 male, 15 female). Sixteen individuals had tooth extraction or implant
surgery in the Implant Clinic of Yonsei University Dental Hospital from 2008 to 2013. These
patients had a history of bisphosphonate medication with varying duration, presence of
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exposed bone in the maxillofacial region for more than eight weeks, and no history of radiation
therapy to the jaws.
3. Control Data Set
126 randomized subsamples from the GSK project (Koreans; 109 male and 17 female) were
used as the control data set. The subsamples from the reference population consisted of healthy
Koreans regardless of gender and age originally recruited for a thyroid cancer study (GSK proj-
ect) (S1 Table).
4. Sample Collection
The sixteen individuals participating in this study were asked to collect 2 mL of saliva in the
tube of an Oragene DNA Self-Collection kit (DNA GenoTek, Ottawa, Ontraio, Cat. #OG-500).
DNA-preserving solution was mixed with the saliva, which was sent to DNA Link Inc. (Seoul,
South Korea) where collection of genomic DNA, extraction of DNA, and further analysis
were completed.
5. Whole Exome Sequencing on HISEQ 2500 using SureSelect All Exon
kit 50Mb
Whole Exome Sequencing was done following the protocol reported in a previous study [53].
6. Whole Exome Sequencing and variant analysis
Sequence QC was done through FastqQC 0.10.1, and then mapped to human reference genome
sequence NCBI b37 using bwa v0.7.5a. BAM files were realigned with the Genome Analysis
Toolkit 2.8–1 (GATK) IndelRealigner, and base quality scores were recalibrated using the
GATK base quality recalibration tool. Variants were called with GATK’s UnifiedGenotyper
tool. In order to filter potential errors, GATK Variant Quality Score Recalibration (VQSR) was
conducted based on hapmap 3.3, NCBI Variation Database (dbSNP138), 1000 genome, and an
Omni 2.5M SNP chip array. Then, the variants’ functional information was annotated using
SnpEff v3.6h with the GRCh37.75 reference set. Variants found were then processed to find
impact variants, i.e., moderate and high variants as well as variants with call rates over 90% (S2
Table). High impact variants are those variants that have a disruptive impact in protein and are
likely to affect the function of the protein, whereas moderate impact variants are those that
may or may not affect the protein. Genomic Evolutionary Rate Profiling (GERP) and Polymor-
phism Phenotyping v2 (polyPhen-2) scores were applied to the variants that matched the crite-
ria and those that showed significance were subject to further statistical analysis. For samples
showing no result, a GERP greater than 2, or Polyphen-2 results with D were filtered during
this analysis.
7. Statistical analysis
Fisher’s exact test was carried out to assess the significance of the variants in BRONJ patients.
Allelic, dominant, and recessive models were tested and variants with p-value< 0.05 were cho-
sen for each model. In this study, a 0.05 cutoff indicates a broad view of association between
the phenotype and genotype in the data. The results were examined for multiple testing prob-
lems. Bonferroni correction with a stricter cutoff of 3.75E-6 for statistical significance found
significant variants. Initially 15 variant genes were obtained by using Bonferroni correction
with a stricter cut-off (p-value< 3.75E-6). However, the initial gene set obtained was not suffi-
cient for the function enrichment analysis. In this study, rather than analyzing the direct effect
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of disease genes, the relationship between genetic variants in a functional network were ana-
lyzed. Therefore, the initial gene set was expanded for further functional network analysis with
a less strict cut-off (p-value<0.05). As a result, 201 variant genes were obtained for the analysis
of functional association of pathogenesis of BRONJ. The significant SNPs were not emphasized
with Bonferroni correction because the main focus of the analysis was to find functional signifi-
cance rather than statistical significance with testing. A call rate of greater than 90% was used.
Three different analysis models (dominant, recessive, and allelic) were used to compare geno-
type frequencies. In a dominant model, a group of homozygote of the major frequency allele
(A) was compared with homozygote of minor allele (B) plus heterozygote (AA vs. AB+BB). In
contrast to the dominant model, the recessive model compared a group of homozygote of
major allele and heterozygote with a group of homozygote of minor allele (AA+AB vs. BB). Fi-
nally, the allelic model compared the number of major and minor alleles (A vs. B) in cases
and controls.
8. Gene set enrichment analysis
Gene set enrichment analysis (DAVID Bioinformatics Resource 6.7) was used to perform a
cluster analysis of variants found through Fisher’s exact test. GSEA was applied to investigate
genetic variants in groups of genes sharing a common biological function, domain, or pathway.
With the GSEA results, cluster enrichment analysis was performed to build a protein function-
al network. The following categories in DAVID were used. In the ‘‘Functional Categories” sec-
tion, ‘‘COG ONTOLOGY” and ‘‘UP SEQ FEATURE;” in the ‘‘Gene Ontology” section:
‘‘GOTERM BP FAT”, ‘‘GOTERM CC FAT,” and ‘‘GOTERMMF FAT;” in the ‘‘Protein Do-
mains” section, ‘‘INTERPRO,” “PIR SUPERFAMILY,” and ‘‘SMART;’ and finally, in the ‘‘Path-
ways” section, ‘‘KEGG PATHWAY” was used. If the cluster had more than one annotation
term in “Initial Group membership” of Classification Stringency Options, “Final Group Mem-
bership” was adjusted to “2” in order to set the cluster.
9. Construction of a protein functional network
A protein functional network was visualized using the top ten clusters of the highest enrich-
ment scores. If different terms shared two or more genes, a link was made. Link thickness rep-
resents the number of genes shared among distinct terms and node size shows the number of
genes in each term. Fig. 1 outlines the filtration and prioritization framework used for
data analysis.
Results
All individuals had a history of BP medication with varying duration. Information regarding
all 16 individuals is provided in S3 Table. An average of 67,035,644 reads and 6,771 megabases
were obtained from the sixteen individual’s WES results. An average of 4,138,925,783.75 total
bases was aligned with a mean coverage depth of 80.36. All information regarding number of
reads, sample coverage, and sequencing depth, as well as data quality, is summarized in S4
Table.
A total of 142 samples (16 case samples and 126 Korean GSK samples) were used for the ini-
tial variant call. The selection yielded 219,722 variants, which were then processed to find im-
pact variants (moderate and high variants as well as variants with a call rate over 90%). 69,187
variants were found to match the criteria, 13,325 variants showing significance based on GERP
and polyPhen scores. Fisher’s Exact test was used to improve statistical power and 201 variants
were found to have a p-values< 0.05 (S5 Table). Variants chosen were selected for subsequent
gene set enrichment analysis. All whole exome sequencing raw data was submitted to the SRA
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database (SRA, http://trace.ncbi.nlm.nih.gov/Traces/sra/, accession number SRP045344). Vari-
ants with affected number = 0 were included in the data analysis because the conserved se-
quences in patients data showed meaningful differences compared to the control set. The genes
with “affected number = 0” have conserved sequences in our 16 patient dataset while in the 126
control dataset, the same genes showed multiple variations in the sequences [54,55].
DAVID (DAVID v6.7) was used to canvass BRONJ pathogenic genes for enriched function-
al-related gene groups. GSEA detected multiple gene sets related to cell adhesion, regulation of
Fig 1. An outline of variant selection for data analysis.
doi:10.1371/journal.pone.0118084.g001
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cell morphology, and post-translational modification. Protein functional network analysis was
then performed to see how genes from different domains related with each other in a biological
system and how interactions between genes might affect pathogenesis of BRONJ. To better un-
derstand the function of genetic variants from BRONJ patients, we searched for significantly
enriched gene function clusters (S6 Table). Cluster enrichment was performed for the whole
list of genes with mutations and the top 10 enriched clusters were picked for protein functional
network analysis based on p-value. Multiple testing corrections like Benjamini method was
routinely used to reduce false positive functional terms, however, at the same time, its strict
cutoff may have disrupted the selection of significant clusters among multiple gene sets[54].
Therefore, although significant pathways were not found from Benjamini correction, gene
functions and pathways were selected with p-value analysis (p-value< 0.05, cluster enrichment
score> 1.3, refer to Table 1 legend). The purpose of this study was to depict how genetic vari-
ants are related to each other in a biological system and to find their associations among en-
riched functions that may affect the pathogenesis of BRONJ as a group of genes.
We provide a list of all annotation terms in each cluster as S4 Table. Enrichment score is the
geometric mean of all the enrichment P-values for each annotations term associated with the
genes in genetic variant list from BRONJ patients. P-value of each term in each cluster means
the significance of the term enrichment with a modified Fisher’s exact test. Enrichment score
of 1.3 is equivalent that average of P-values of the terms in cluster is 0.05. Count and percentage
(%) in the table show the number of genes that are involved in the annotation term and the
ratio of genes related with the term to total genetic variants. Benjamini is one of the multiple
testing correction techniques.
Representative terms in each cluster were listed in Table 1. Protein functional network anal-
ysis (Fig. 2) showed numerous mutations in genes affecting cell morphology and cell adhesion
and binding. Functional terms and the number of shared genes between two terms in the pro-
tein functional network analysis were described using circles, nodes, and lines. Nodes describe
functional terms in each cluster, lines express the number of genes shared by each term, node
size indicates the number of genetic variants, and link thickness signifies the number of shared
genes. Yellow circles represent enriched clusters of gene functions involved in the regulation of
cytoskeleton, cell adhesion, and regulation of post-translational modification. These clusters
are linked through genes related to post-translational modification such as those affecting ubi-
quitin-like proteins (UBLs) and isopeptide bonds. UBLs are known to influence substrate affin-
ity, localization, and stability of other proteins by forming isopeptide bonds [55]. Cytoskeletal
proteins such as tubulin, actin, and myosin also form isopeptide bonds with the extracellular
matrix-associated proteins including collagen, fibronectin, and laminin [56,57].
Discussion
As it was indicated earlier, the aim of this study was to identify all the biomarkers associated
with BRONJ by comparing the genetic information of experimental group with the control
group. Generally, in other studies with Whole Exome Sequencing, multiple methods were used
to validate the result of variant calling in an effort to minimize the error in the process. Howev-
er, in this study the validation of variant calling was not performed, because the main focus of
this study was to identify new variants associated with BRONJ rather than to identify the loca-
tion of affected transcript in the mutation. One of the limitations of this study was that al-
though Whole Exome Sequencing is effective in finding the variants responsible for BRONJ, it
cannot find the structural information about variants [59]. If one wants to find the affected
transcript in variants as is in many researches on cancer or tumor, transcriptome sequencing
with different genome sample is necessary. Because this study used saliva samples as a method
Investigation of BRONJ Biomarkers
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Table 1. Top 10 clusters ranked by enrichment score and representative terms in each cluster from GSEA results (based on DAVID).
Nebulin Enrichment Score: 2.84
Category Term Count % P-value Benjamini
INTERPRO Nebulin 35 residue motif 3 1.55 6.72E-04 0.09
INTERPRO Nebulin 3 1.55 6.72E-04 0.09
SMART NEBU 3 1.55 8.28E-04 0.09
Basal plasma membrane Enrichment Score: 2.53
Category Term Count % P-value Benjamini
GOTERM_CC_FAT basolateral plasma membrane 9 4.64 2.01E-03 0.41
GOTERM_CC_FAT basal plasma membrane 4 2.06 2.95E-03 0.18
GOTERM_CC_FAT basal part of cell 4 2.06 4.46E-03 0.18
Cytoskeleton Enrichment Score: 1.83
Category Term Count % P-value Benjamini
GOTERM_CC_FAT cytoskeleton 28 14.43 2.68E-03 0.21
GOTERM_CC_FAT cytoskeletal part 21 10.82 4.59E-03 0.16
GOTERM_CC_FAT microtubule cytoskeleton 13 6.70 2.02E-02 0.32
EGF Enrichment Score: 1.81
Category Term Count % P-value Benjamini
INTERPRO EGF-like region, conserved site 12 6.19 3.20E-04 0.13
INTERPRO EGF-like, type 3 8 4.12 4.89E-03 0.23
INTERPRO EGF calcium-binding 5 2.58 7.37E-03 0.27
Ubl & Isopeptide bond Enrichment Score: 1.81
Category Term Count % P-value Benjamini
SP_PIR_KEYWORDS ubl conjugation 14 7.22 6.01E-03 0.23
SP_PIR_KEYWORDS isopeptide bond 8 4.12 4.05E-02 0.42
Immunoglobulin Enrichment Score: 1.74
Category Term Count % P-value Benjamini
INTERPRO Fibronectin, type III-like fold 9 4.64 8.23E-04 0.09
INTERPRO Fibronectin, type III 9 4.64 1.01E-03 0.08
SMART FN3 9 4.64 1.88E-03 0.11
Cell adhesion Enrichment Score: 1.70
Category Term Count % P-value Benjamini
GOTERM_CC_FAT proteinaceous extracellular matrix 11 5.67 3.19E-03 0.16
GOTERM_CC_FAT extracellular matrix 11 5.67 5.40E-03 0.16
SP_PIR_KEYWORDS cell binding 3 1.55 9.46E-03 0.25
SH3 Enrichment Score: 1.68
Category Term Count % P-value Benjamini
SP_PIR_KEYWORDS sh3 domain 8 4.12 5.09E-03 0.23
INTERPRO Src homology-3 domain 7 3.61 2.70E-02 0.47
INTERPRO Variant SH3 4 2.06 3.23E-02 0.51
Protease Enrichment Score: 1.65
Category Term Count % P-value Benjamini
PIR_SUPERFAMILY serpin 4 2.06 6.23E-03 0.43
INTERPRO Protease inhibitor I4, serpin 4 2.06 8.87E-03 0.30
SMART SERPIN 4 2.06 1.18E-02 0.25
Motor protein Enrichment Score: 1.63
Category Term Count % P-value Benjamini
INTERPRO Dynein heavy chain, N-terminal region 2 4 2.06 6.06E-04 0.12
INTERPRO Dynein heavy chain 4 2.06 6.06E-04 0.12
GOTERM_CC_FAT dynein complex 4 2.06 6.37E-03 0.17
doi:10.1371/journal.pone.0118084.t001
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of collecting DNA, transcriptome sequencing could not be done because it requires tissue sam-
ples. The method of whole exome sequencing was adequate for the purpose of this research,
which was to detect all the variants associated with BRONJ. However, in in order to study these
variants in depth, future study is warranted with transcriptome sequencing, which will allow
detection of affected transcript within these variants.
The subjects in the experimental and control groups differed considerably in gender selec-
tion. The experimental group had more female participants whereas the control group had
more male subjects. Gender bias in the experimental group was accidental and inevitable due
to the nature of this study. Currently, bisphosphonates are widely prescribed for patients with
osteoporosis. Since osteoporosis is more prevalent in female, bisphosphonate is used more
among females. Due to higher use of bisphosphonates in female, higher representation of fe-
male patients with bisphosphonate-associated BRONJ was expected in experimental group. Be-
cause the incidence of BRONJ is low, the gender difference in incidence remains unknown and
needs further study. The effect of gender bias in our experimental group in this study is not
clear [50,58,59].
Despite many hypotheses (including remodeling suppression, infection, and angiogenesis
disorder), the exact mechanism behind BRONJ is still unclear [60]. Remodeling suppression
through inhibition of the mevalonate pathway is the best-known hypothesis. Nitrogen-
containing BPs that inhibit the mevalonate pathway in osteoclast interfere with post-
translational modification by blocking membrane transport across the endoplasmic reticulum.
Fig 2. Analysis of gene function enrichment and construction of functional network. Each cluster is represented as a yellow circle, in which nodes
show all terms included in the cluster. A representative term was selected to describe each cluster. Node size shows the number of genes mapped in the
network. Nodes were color-coded according to their characteristics: genes related to cell morphology (pink), cell adhesion and binding (green), Ubiquitin-like
proteins and isopeptide bond (red), and proteases (yellow). If different terms share two or more genes, a link was given. Links express the number of genes
shared among distinct terms.
doi:10.1371/journal.pone.0118084.g002
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BPs absorbed by osteoclast act as an inhibitor of farnesyl pyrophosphate synthase, an ubiqui-
tin-like protein, preventing the biosynthesis of small GTPase signaling proteins [2]. These
GTP-binding proteins (Ras, Pho, Rac, Rab) are important for cellular growth and are involved
in cytoskeletal activity of bone-resorbing osteoclasts [61,62]. Transport across the endoplasmic
reticulum is interrupted in the process so that ruffled borders no longer form along the osteo-
clast cell membrane [26]. As a result, sequestrum is found where necrosis has occurred in the
bone remodeling process. As mentioned earlier, BRONJ may be due to combination of predis-
posing factors and multigentic factors. This study attempted to find a multigenic module re-
sponsible for BRONJ [32,35,38]. Of the 201 significant variables found in this study, the
highest 10 variants with the lowest p-values were looked at for their effect on BRONJ. Genes
ARSD, SLC25A5, CCNYL2, PGYM were among the top 10 variants found. One functionally
relevant gene was ARSD, which codes for the protein which participates in bone composition.
SLC25A5 is known to code for the protein responsible for transferring energy in the cell and
whose mutation may lead to dysfunction in cell metabolism [2]. These genes did not have a di-
rect phenotypical effect on BRONJ but may participate in cell morphology and cell function. It
has been reported that transglutaminase regulates the bone remodeling process by forming iso-
peptide bonds during protein post-translational modification. Transglutaminase is an Ubiqu-
tin-like protein which modulates GTPase activity. The enzyme behaves as a multifunctional
protein involved in inflammatory effects through GTP hydrolyzation and protein cross linking.
BPs interfere with transglutaminase regulation and inhibit osteoclast activity.
In this study, we found genetic mutations in variants which regulate post-translational mat-
uration. Significant differences between BRONJ patients and the control group appeared in
genes related to ubiquitin-like proteins, isopeptide bonds, cell adhesion, and cytoskeleton.
These genes are responsible for post-translational maturation and can affect cell differentiation
[57]. The results from this study suggest that BRONJ-inducing factors are genetically associat-
ed and that BRONJ arises due to the malfunctioning of post-translational modification in oste-
oclast, leading to the impairment of cell morphology and adhesion.
Despite all statistics regarding BRONJ and BP prescriptions given to osteoporosis patients,
the effect of BP use needs to be ascertained by classifying all complications that arise in medical
procedures. Among the few BRONJ diagnostic methods are serodiagnosis such as serum CTX
(carboxy-terminal collagen crosslinks) and measuring the level of osteocalcin to diagnose the
risk of developing BRONJ. Radiologic examination such as bone scintigraphy and MRI are
often used in current clinical practice despite their inaccuracy because there is no better diag-
nostic tool for measuring the risk of developing BRONJ at this point [63,64]. It is thus essential
to develop an innovative diagnostic tool for BRONJ.
Conclusion
BP in the biological system is known to inhibit osteoclastic bone resorption via phagocytosis
and internalization by osteoclasts, triggering apoptosis of osteoclasts and eventually inhibiting
osteoclast-mediated bone resorption. BPs inhibit the post-translational modification process
by blocking the mevalonate pathway in osteoclast and preventing ruffled borders from forming
along the osteoclast cell membrane. In this study a significant difference between BRONJ pa-
tients and randomized subsamples group was found in genes related to ubiquitin-like proteins,
isopeptide bonds, cell adhesion, and cytoskeleton, all of which are involved in post-
translational maturation. One may conclude that BRONJ-inducing factors are genetically asso-
ciated and cause the malfunctioning of post-translational modification in osteoclast leading
to the impairment of cell morphology and adhesion. Genetic diagnosis of BRONJ can help
clinicians determine appropriate treatment and thus reduce possible complications. Also,
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post-translational maturation in the mevalonate pathway can be further investigated through
genetic research similar to the current study to elucidate the mechanism of BRONJ pathogene-
sis in detail. Further research with more cases and controls, along with functional animal stud-
ies, may produce legitimate biomarkers for early diagnosis of BRONJ.
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